ZBZuzana J. Berrong

Zuzana J. Berrong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zuzana J. Berrong has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity

    by Madhav D. Sharma, Rafal Pacholczyk, Huidong Shi, Zuzana J. Berrong, Yousef Zakharia, Austin Greco, Chang-Sheng S. Chang, Sudharshan Eathiraj, Eugene Kennedy, Thomas Cash, et al.


  • Open Access

    Transcriptomes and shRNA Suppressors in a TP53 Allele–Specific Model of Early-Onset Colon Cancer in African Americans

    by Charles C. Weige, Marc R. Birtwistle, Himel Mallick, Nengjun Yi, Zuzana Berrong, Emily Cloessner, Keely Duff, Josephine Tidwell, Megan Clendenning, Brent Wilkerson, et al.

    African Americans are disproportionately affected by early-onset, high-grade malignancies. A fraction of this cancer health disparity can be explained by genetic differences between individuals of African or European descent. Here the wild-type Pro/Pro genotype at the TP53Pro72Arg (P72R) polymorphism (SNP: rs1042522) is more frequent in African Americans with cancer than in African Americans without cancer (51% vs. 37%), and is associated with a significant increase in the rates of cancer diagnosis in African Americans. To test the hypothesis that Tp53 allele–specific gene expression may contribute to African American cancer disparities, TP53 hemizygous knockout variants were generated and characterized in the RKO colon carcinoma cell line, which is wild type for TP53 and heterozygous at the TP53Pro72Arg locus. Transcriptome profiling, using RNAseq, in response to the DNA-damaging agent etoposide revealed a large number of Tp53-regulated transcripts, but also a subset of transcripts that were TP53Pro72Arg allele specific. In addition, a shRNA-library suppressor screen for Tp53 allele–specific escape from Tp53-induced arrest was performed. Several novel RNAi suppressors of Tp53 were identified, one of which, PRDM1β (BLIMP-1), was confirmed to be an Arg-specific transcript. Prdm1β silences target genes by recruiting H3K9 trimethyl (H3K9me3) repressive chromatin marks, and is necessary for stem cell differentiation. These results reveal a novel model for African American cancer disparity, in which the TP53 codon 72 allele influences lifetime cancer risk by driving damaged cells to differentiation through an epigenetic mechanism involving gene silencing. Implications: TP53 P72R polymorphism significantly contributes to increased African American cancer disparity. Mol Cancer Res; 12(7); 1029–41. ©2014 AACR.